Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.

Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F.

Am J Med Genet A. 2018 Dec;176(12):2924-2929. doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10.

PMID:
30302932
2.

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.

Moschetti V, Kim M, Sand M, Wunderlich G, Andersen G, Feifel U, Jang IJ, Timmer W, Rosenbrock H, Boland K.

Eur Neuropsychopharmacol. 2018 May;28(5):643-655. doi: 10.1016/j.euroneuro.2018.01.003. Epub 2018 Mar 19.

3.

NIH workshop report on the trans-agency blood-brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface.

Ochocinska MJ, Zlokovic BV, Searson PC, Crowder AT, Kraig RP, Ljubimova JY, Mainprize TG, Banks WA, Warren RQ, Kindzelski A, Timmer W, Liu CH.

Fluids Barriers CNS. 2017 May 1;14(1):12. doi: 10.1186/s12987-017-0061-6. Review.

4.

Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open-label, crossover phase 1 study.

Calcagnile S, Lanzarotti C, Gutacker M, Jakob-Rodamer V, Peter Kammerer K, Timmer W.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):377-86. doi: 10.1002/cpdd.192. Epub 2015 May 29.

PMID:
27137147
5.

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.

N Engl J Med. 2015 May 21;372(21):1987-95. doi: 10.1056/NEJMoa1411776. Epub 2015 May 17.

6.

Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma.

Homburg U, Renz H, Timmer W, Hohlfeld JM, Seitz F, Lüer K, Mayer A, Wacker A, Schmidt O, Kuhlmann J, Turowska A, Roller J, Kutz K, Schlüter G, Krug N, Garn H.

J Allergy Clin Immunol. 2015 Sep;136(3):797-800. doi: 10.1016/j.jaci.2015.02.018. Epub 2015 Apr 2. No abstract available.

PMID:
25842286
7.

Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.

Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27.

8.

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.

Spinelli T, Moresino C, Baumann S, Timmer W, Schultz A.

Springerplus. 2014 Jul 29;3:389. doi: 10.1186/2193-1801-3-389. eCollection 2014.

9.

First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist.

Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S.

J Clin Pharmacol. 2014 Dec;54(12):1347-53. doi: 10.1002/jcph.355. Epub 2014 Jul 8.

PMID:
24989946
10.

Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.

Baldoni D, Gutierrez M, Timmer W, Dingemanse J.

J Antimicrob Chemother. 2014 Mar;69(3):706-14. doi: 10.1093/jac/dkt401. Epub 2013 Oct 8.

PMID:
24106141
11.

Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.

Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W.

Support Care Cancer. 2013 Oct;21(10):2879-87. doi: 10.1007/s00520-013-1857-9. Epub 2013 Jun 11.

PMID:
23748441
12.

Response to the letter by Dr Chin and co-workers.

Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, Reilly PA.

Br J Clin Pharmacol. 2013 Feb;75(2):556. doi: 10.1111/j.1365-2125.2012.04407.x. No abstract available.

13.

Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.

Lindskov Krog P, Osterberg O, Gundorf Drewes P, Rembratt Å, Schultz A, Timmer W.

Eur J Drug Metab Pharmacokinet. 2013 Mar;38(1):43-51. doi: 10.1007/s13318-012-0100-2. Epub 2012 Sep 5.

PMID:
22948856
14.

A Thorough QT Study of Teduglutide in Healthy Subjects.

Hartmann M, Timmer W, Schultz A, Nave R, Luehmann R, Krause S, Lahu G, Scholpp J.

Clin Pharmacol Drug Dev. 2012 Apr;1(2):57-66. doi: 10.1177/2160763X12438745.

PMID:
27121220
15.

Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, Reilly PA.

Br J Clin Pharmacol. 2012 Sep;74(3):490-500. doi: 10.1111/j.1365-2125.2012.04218.x.

16.

Principles and current strategies for targeting autophagy for cancer treatment.

Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E.

Clin Cancer Res. 2011 Feb 15;17(4):654-66. doi: 10.1158/1078-0432.CCR-10-2634. Review.

17.

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.

Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, Orr MS, Sridhara R, Booth B, Leighton JK, Timmer W, Harapanhalli R, Dagher R, Justice R, Pazdur R.

Clin Cancer Res. 2008 Sep 1;14(17):5325-31. doi: 10.1158/1078-0432.CCR-08-0308.

18.

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

Rabe KF, Timmer W, Sagkriotis A, Viel K.

Chest. 2008 Aug;134(2):255-262. doi: 10.1378/chest.07-2138. Epub 2008 Apr 10.

PMID:
18403672
19.

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.

Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R.

Clin Cancer Res. 2008 Jan 15;14(2):352-9. doi: 10.1158/1078-0432.CCR-07-4175.

20.

A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.

Voshaar T, Lapidus R, Maleki-Yazdi R, Timmer W, Rubin E, Lowe L, Bateman E.

Respir Med. 2008 Jan;102(1):32-41. Epub 2007 Nov 8.

21.

Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease.

Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, Scheuch G.

J Clin Pharmacol. 2007 Oct;47(10):1335-41. Epub 2007 Jul 11.

PMID:
17625157
22.

Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide.

Weinbrenner A, Hüneke D, Zschiesche M, Engel G, Timmer W, Steinijans VW, Bethke T, Wurst W, Drollmann A, Kaatz HJ, Siegmund W.

J Clin Endocrinol Metab. 2002 May;87(5):2160-3.

PMID:
11994358
23.

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.

Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W.

J Clin Pharmacol. 2002 Mar;42(3):297-303.

PMID:
11865966
24.

The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.

Schmidt BM, Kusma M, Feuring M, Timmer WE, Neuhäuser M, Bethke T, Stuck BA, Hörmann K, Wehling M.

J Allergy Clin Immunol. 2001 Oct;108(4):530-6.

PMID:
11590377
25.

The FDA and The Lancet: an exchange.

Hirschfeld S, Kieffer L, McGuinn WD, Rothmann M, Timmer WC.

Lancet. 2001 Aug 4;358(9279):415-6; author reply 417-8. No abstract available.

PMID:
11503618
26.

Effect of vegetable and carotenoid consumption on aberrant crypt multiplicity, a surrogate end-point marker for colorectal cancer in azoxymethane-induced rats.

Rijken PJ, Timmer WG, van de Kooij AJ, van Benschop IM, Wiseman SA, Meijers M, Tijburg LB.

Carcinogenesis. 1999 Dec;20(12):2267-72.

PMID:
10590218
27.

The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis.

Schmidt BM, Timmer W, Georgens AC, Hilt M, Mattinger C, Wurst W, Hörmann K, Wehling M.

J Clin Pharmacol. 1999 Oct;39(10):1062-9.

PMID:
10516941
28.

Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole.

Hartmann M, Ehrlich A, Fuder H, Lühmann R, Emeklibas S, Timmer W, Wurst W, Lücker PW.

Aliment Pharmacol Ther. 1998 Oct;12(10):1027-32.

29.

The association of increasing dietary concentrations of fish oil with hepatotoxic effects and a higher degree of aorta atherosclerosis in the ad lib.-fed rabbit.

Ritskes-Hoitinga J, Verschuren PM, Meijer GW, Wiersma A, van de Kooij AJ, Timmer WG, Blonk CG, Weststrate JA.

Food Chem Toxicol. 1998 Aug;36(8):663-72.

PMID:
9734717
30.

Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.

Kleist P, Ehrlich A, Suzuki Y, Timmer W, Wetzelsberger N, Lücker PW, Fuder H.

Eur J Clin Pharmacol. 1997;53(2):149-52.

PMID:
9403288
31.
32.

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man.

Ehrlich A, Fuder H, Hartmann M, Wieckhorst G, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW.

Eur J Clin Pharmacol. 1996;51(3-4):277-81.

PMID:
9010699
33.

Effects of two dietary fat levels and four dietary linoleic acid levels on mammary tumor development in Balb/c-MMTV mice under ad libitum feeding conditions.

Ritskes-Hoitinga J, Meijers M, Timmer WG, Wiersma A, Meijer GW, Weststrate JA.

Nutr Cancer. 1996;25(2):161-72.

PMID:
8710685
34.

Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.

Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lücker PW, Fuder H.

Methods Find Exp Clin Pharmacol. 1995 Sep;17(7):489-95.

PMID:
8577212
35.

Furocoumarin-photosensitized hydroxylation of guanosine in RNA and DNA.

Wamer WG, Timmer WC, Wei RR, Miller SA, Kornhauser A.

Photochem Photobiol. 1995 Apr;61(4):336-40.

PMID:
7537887
36.

Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants.

Bressler P, Brown K, Timmer W, Bours V, Siebenlist U, Fauci AS.

J Virol. 1993 Jan;67(1):288-93.

37.
38.

[Coccidiosis in lambs: observations in the preventive use of an amprolium-containing medicated feed].

Talmon P, Jager LP, de Leeuw WA, Timmer WJ.

Tijdschr Diergeneeskd. 1989 Jun 1;114(11):611-7. Dutch.

PMID:
2741152
39.

Nutritional evaluation of low-erucic-acid rapeseed oils.

Vles RO, Bijster GM, Timmer WG.

Arch Toxicol Suppl. 1978;(1):23-32.

PMID:
277106

Supplemental Content

Loading ...
Support Center